arrow
M

María Isabel Casas

seguro social de salud del peru
H指数:11
被引数:799

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase Ib safety and efficacy of nadunolimab/gemcitabine/carboplatin in mTNBC
2023-10-010
PRE
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

PEARL研究中激素受体阳性、HER2-negative转移性乳腺癌绝经后患者接受palbociclib联合内分泌治疗与卡培他滨治疗的总生存率比较

2022-06-0112
OA
GEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy in postmenopausal women with HR (hormone receptor)+/HER2-endocrine sensitive advanced breast cancer (ABC)
2020-09-014
OAAI
Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study
2020-05-010
OAAI
Phase III trial to evaluate patient's preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive advanced breast cancer (ABC) under IV trastuzumab (IV-t) treatment for at least 4 months. ChangHER-SC study (GEICAM/2012-07)
2017-02-150
PRE
Phase III study of palbociclib (PD-0332991) in combination with endocrine therapy (exemestane or fulvestrant) versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to aromatase inhibitors. The PEARL study (GEICAM/2013-02)
2017-02-152
PRE
ACE and CXCL10 as predictive biomarkers in the LEA study
2016-10-010
OAAI